The distribution and characteristics of LDL receptor mu
review

Scientific Reports

5, 17272

DOI: 10.1038/srep17272

Citation Report

#	Article	IF	Citations
1	Characterization of the unique Chinese W483XÂmutation in the low-density lipoproteinâ€“receptor gene in young patients with homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 538-546.e5.	0.6	17
2	Familial defective apolipoprotein B-100: a tale of twin mutations. Journal of Clinical Lipidology, 2016, 10, 1050-1051.	0.6	4
3	Extremely severe aortic stenosis developed in a young female patient with underdiagnosis of homozygous familial hypercholesterolemia: An 8-year follow-up. International Journal of Cardiology, 2016, 207, 372-374.	0.8	3
4	The genetic spectrum of familial hypercholesterolemia in the central south region of China. Atherosclerosis, 2017, 258, 84-88.	0.4	22
5	Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene. Atherosclerosis, 2017, 263, 163-170.	0.4	13
6	Recognition, diagnosis and treatment of homozygous familial hypercholesterolemia. Expert Opinion on Orphan Drugs, 2017, 5, 933-943.	0.5	0
7	Role of sEH R287Q in LDLR expression, LDL binding to LDLR and LDL internalization in BEL-7402 cells. Gene, 2018, 667, 95-100.	1.0	3
8	Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study. Atherosclerosis, 2018, 269, 106-116.	0.4	22
9	Compound heterozygous familial hypercholesterolemia in a Chinese boy with a deÂnovo and transmitted low-density lipoprotein receptor mutation. Journal of Clinical Lipidology, 2018, 12, 230-235.e6.	0.6	8
10	Genetic analysis in a compound heterozygote family with familial hypercholesterolemia. Molecular Medicine Reports, 2018, 17, 8439-8449.	1.1	2
11	Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation. Lipids in Health and Disease, 2018, 17, 252.	1.2	19
12	Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan. Atherosclerosis, 2018, 277, 440-447.	0.4	11
13	Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries. Atherosclerosis, 2018, 279, 62-72.	0.4	19
14	Detection of Familial Hypercholesterolemia Using Next Generation Sequencing in Two Population-Based Cohorts. Chonnam Medical Journal, 2018, 54, 31.	0.5	10
15	Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1209-1216.	0.9	1
16	Genetic variations in familial hypercholesterolemia and cascade screening in East Asians. Molecular Genetics & Genomic Medicine, 2019, 7, e00520.	0.6	12
17	Independent Severe Cases of Heterozygous Familial Hypercholesterolemia Caused by the W483X and Novel W483G Mutations in the Low-Density Lipoprotein Receptor Gene That Were Clinically Diagnosed as Homozygous Cases. Genetic Testing and Molecular Biomarkers, 2019, 23, 401-408.	0.3	3
18	Current Status of Familial Hypercholesterolemia in China: A Need for Patient FH Registry Systems. Frontiers in Physiology, 2019, 10, 280.	1.3	27

#	Article	IF	Citations
19	Cascade screening for familial hypercholesterolemia-identification of the C308Y mutation in multiple family members and relatives for the first time in mainland China. BMC Medical Genetics, 2019, 20, 173.	2.1	2
20	Current status of familial hypercholesterolemia in Chinese populations. Current Opinion in Lipidology, 2019, 30, 94-100.	1.2	12
21	Systematic prediction of familial hypercholesterolemia caused by low-density lipoprotein receptor missense mutations. Atherosclerosis, 2019, 281, 1-8.	0.4	10
22	Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction. Clinical Cardiology, 2019, 42, 385-390.	0.7	14
23	Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature. Journal of Clinical Lipidology, 2020, 14, 639-645.	0.6	1
24	Genetic Diagnosis of Familial Hypercholesterolemia in Asia. Frontiers in Genetics, 2020, 11, 833.	1.1	13
25	Genetics, Screening, and Treatment of Familial Hypercholesterolemia: Experience Gained From the Implementation of the Vietnam Familial Hypercholesterolemia Registry. Frontiers in Genetics, 2020, 11, 914.	1.1	6
26	Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Responseâ€”What is First?. International Journal of Molecular Sciences, 2020, 21, 2716.	1.8	16
27	Actionable secondary findings in 1116 Hong Kong Chinese based on exome sequencing data. Journal of Human Genetics, 2021, 66, 637-641.	1.1	3
28	Familial hypercholesterolemia in Southeast and East Asia. American Journal of Preventive Cardiology, 2021, 6, 100157.	1.3	7
29	Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen. Frontiers in Medicine, 2021, 8, 694668.	1.2	8
30	Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia. Frontiers in Genetics, 2021, 12, 650077.	1.1	2
31	The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia. Lipids in Health and Disease, 2021, 20, 101.	1.2	3
32	Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2022, 29, 639-653.	0.9	11
33	A systematic review of LDLR, PCSK9, and APOB variants in Asia. Atherosclerosis, 2020, 305, 50-57.	0.4	6
34	Genetically confirmed familial hypercholesterolemia in outpatients with hypercholesterolemia. Journal of Geriatric Cardiology, 2018, 15, 434-440.	0.2	9
36	Low-density lipoprotein receptor gene mutationÂat Exon 2 and 4 in premature coronary artery disease in our population. Pakistan Journal of Medical Sciences, 2019, 35, 1143-1148.	0.3	0
37	Development of an Optimized Tetra-Amplification Refractory Mutation System PCR for Detection of 12 Pathogenic Familial Hypercholesterolemia Variants in the Asian Population. Journal of Molecular Diagnostics, 2022, 24, 120-130.	1.2	0

#	Article	IF	Citations
38	Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study. Journal of Clinical Lipidology, 2022, 16, 306-314.	0.6	4
39	Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report. World Journal of Clinical Cases, 2022, 10, 6728-6735.	0.3	2
40	Expanding the genetic spectrum for Chinese familial hypercholesterolemia population with six genetic mutations identified using a nextâ€generation sequencingâ€based laboratoryâ€developed screening test. Molecular Genetics & Genomic Medicine, 0, , .	0.6	2
41	Whole genome sequence analysis of blood lipid levels in >66,000 individuals. Nature Communications, 2022, 13, .	5.8	26